Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $958.40 million for fiscal year 2025.
MADRIGAL PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $958.40M | +432.1% |
| 2024 | $180.13M | — |
| 2023 | $0.00 | — |
| 2022 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $287.27M | +362.0% | +35.0% |
| June 30, 2025 | $212.80M | +1353.8% | +55.0% |
| March 31, 2025 | $137.25M | — | +120.7% |
| September 30, 2024 | $62.17M | — | +324.8% |
| June 30, 2024 | $14.64M | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +432.1% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from MADRIGAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: